Intellikine, a privately held La Jolla-based biotech startup with plans for a new cancer drug, said July 8 it has raised $51 million in a preferred stock sale that attracted some well-known names in the drug industry...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99